Type 2 Diabetes Mellitus
Conditions
Brief summary
The purpose of this study is to examine the participant's preference for treatment with once-weekly dosing of DPP-4 inhibitor trelagliptin versus once-daily dosing of DPP-4 inhibitor alogliptin among the participants with type 2 diabetes mellitus who are being treated with once-daily dosing of DPP-4 inhibitor.
Detailed description
The drugs being tested in this study are called Trelagliptin and Alogliptin. This study will look at the participant's preference for treatment with Trelagliptin versus Alogliptin. The study enrolled 60 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups: * Trelagliptin 100 mg, followed by Alogliptin 25 mg * Alogliptin 25 mg, followed by Trelagliptin 100 mg All participants will be asked to take one tablet of trelagliptin orally once a week or one tablet of alogliptin orally once a day throughout the study period. This multi-center trial will be conducted in Japan. The overall time to participate in this study is 16 weeks. Participants will make 3 visits to the clinic.
Interventions
DRUGTrelagliptin
Trelagliptin tablets
DRUGAlogliptin
Alogliptin tablets
Sponsors
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants who have been diagnosed with type 2 diabetes mellitus. 2. Participants who are being treated with any of the following DPP-4 inhibitors for at least 8 weeks prior to the time of informed consent (Week 0). * Sitagliptin : 50 mg once daily * Alogliptin : 25 mg once daily * Linagliptin : 5 mg once daily * Teneligliptin : 20 mg once daily * Saxagliptin : 5 mg once daily 3. Participants who were judged by the investigators possible to change the treatment from daily dosing of DPP-4 inhibitor shown in Inclusion Criteria 2 to study drug trelagliptin 100 mg or alogliptin 25 mg. 4. Participants whose glycosylated hemoglobin (HbA1c) value measured within 8 weeks prior to the time of informed consent (Week 0) is below 10.0%. 5. Participants who responded to Diabetes Treatment Satisfaction Questionnaire (DTSQ) at the time of informed consent (Week 0). 6. Participants who were judged by the investigators capable to understand the contents of this clinical research and comply with them. 7. Participants who are able to sign and date the Informed Consent Form before any clinical research procedure begins. 8. Participants who are at least 20 years old at the time of giving the consent. 9. Participants who are classified as outpatients.
Exclusion criteria
1. Participants who have a history of taking once-weekly dosing of DPP-4 inhibitor (trelagliptin or omarigliptin). 2. Participants who are being treated with drugs other than those for once-daily oral dosing for the purpose of treatment of chronic complication (for example, BENET® Tablets 75 mg, a therapeutic agent for osteoporosis which is administered once monthly). 3. Participants who are being treated with twice-daily dosing of DPP-4 inhibitor (vildagliptin or anagliptin). 4. Participants who are being treated with anti-diabetic fixed-dose combination pill contained a DPP-4 inhibitor. 5. Participants with moderate or severe renal impairment (for example, participant whose estimated glomerular filtration rate (eGFR) is below 60 mL/min/1.73m\^2). 6. Participants for whom blood sugar control by insulin preparations is desired (for example, participants with severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, or serious trauma before or after surgery). 7. Participants who have a history of hypersensitivity or allergy to DPP-4 inhibitor. 8. Participants with serious heart disease, cerebrovascular disorder, or participants with serious disease in the pancreas, blood, etc. 9. Participants with unstable proliferative diabetic retinopathy. 10. Participants with malignant tumor. 11. Participants who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant. 12. Participants participating in other clinical studies. 13. Participants who have been determined as inappropriate participants by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period | At Week 16 | Participants answered standardized questions about their preference of drug therapy for Type 2 Diabetes Mellitus. Participants selected one choice from the following 4 choices; either once-weekly DPP-4 inhibitor or daily DPP-4 inhibitor, once-weekly DPP-4 inhibitor, daily DPP-4 inhibitor, neither once-weekly DPP-4 inhibitor nor daily DPP-4 inhibitor. Reported data was the number of participants with a choice of either trelagliptin (once-weekly DPP-4 inhibitor) or alogliptin (once-daily DPP-4 inhibitor), trelagliptin, alogliptin, neither trelagliptin nor alogliptin. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | At Week 16 | Participants answered standardized questions about their preference of drug therapy for Type 2 Diabetes Mellitus. The preference of drug therapy was categorized by background factors like age (years), gender, height (cm), weight (kg), BMI (kg/m\^2), duration of diabetes (years), work status, alcohol intake history, smoking habits, experience of educational hospitalization on DM, presence of cohabiter, percentage of compliance with DPP-4 inhibitors during 4-weeks before the start of treatment period, number of oral drugs per day at the beginning of treatment period (excluding investigational drug), complication of metabolic syndrome, percentage of HbA1c (NGSP is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at the time of informed consent. |
| Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | At Week 16 | Participants answered standardized questions about their preference of drug therapy for Type 2 Diabetes Mellitus. The preference of drug therapy was categorized by background factors like age (years), gender, height (cm), weight (kg), BMI (kg/m\^2), duration of diabetes (years), work status, alcohol intake history, smoking habits, experience of educational hospitalization on DM, presence of cohabiter, percentage of compliance with DPP-4 inhibitors during 4-weeks before the start of treatment period, number of oral drugs per day at the beginning of treatment period (excluding investigational drug), complication of metabolic syndrome, percentage of HbA1c (NGSP is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at the time of informed consent. |
| Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | At Week 16 | Participants answered standardized questions about their preference of drug therapy for Type 2 Diabetes Mellitus. The preference of drug therapy was categorized by background factors like age (years), gender, height (cm), weight (kg), BMI (kg/m\^2), duration of diabetes (years), work status, alcohol intake history, smoking habits, experience of educational hospitalization on DM, presence of cohabiter, percentage of compliance with DPP-4 inhibitors during 4-weeks before the start of treatment period, number of oral drugs per day at the beginning of treatment period (excluding investigational drug), complication of metabolic syndrome, percentage of HbA1c (NGSP is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at the time of informed consent. |
Countries
Japan
Participant flow
Recruitment details
Participants took part in the study at 2 investigative sites in Japan from 18 August 2017 to 4 February 2018.
Pre-assignment details
Participants with a diagnosis of Type 2 Diabetes Mellitus (DM) were enrolled in 1 of 2 crossover arms: trelagliptin 100 mg then alogliptin 25 mg or alogliptin 25 mg then trelagliptin 100 mg.
Participants by arm
| Arm | Count |
|---|---|
| Trelagliptin 100 mg + Alogliptin 25 mg Trelagliptin preceding group (T-A group): Trelagliptin 100 mg, tablets, orally, once a week for 8 weeks, followed by alogliptin, 25 mg, tablets, orally, once a day for 8 weeks. | 30 |
| Alogliptin 25 mg + Trelagliptin 100 mg Alogliptin preceding group (A-T group): Alogliptin, 25 mg, tablets, orally, once a day for 8 weeks, followed by trelagliptin, 100 mg, tablets, orally, once a week for 8 weeks. | 30 |
| Total | 60 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Treatment Period 1 | Reason not Specified | 0 | 1 |
| Treatment Period 2 | Pretreatment Event/Adverse Event | 0 | 1 |
Baseline characteristics
| Characteristic | Trelagliptin 100 mg + Alogliptin 25 mg | Total | Alogliptin 25 mg + Trelagliptin 100 mg |
|---|---|---|---|
| Age, Continuous | 60.6 years STANDARD_DEVIATION 8.86 | 60.1 years STANDARD_DEVIATION 8.73 | 59.7 years STANDARD_DEVIATION 8.73 |
| Alcohol intake history Non-Drinker | 10 Participants | 20 Participants | 10 Participants |
| Alcohol intake history Occasional Drinker | 1 Participants | 5 Participants | 4 Participants |
| Alcohol intake history Regular Drinker | 19 Participants | 35 Participants | 16 Participants |
| Body Mass Index (BMI) | 24.61 kg/m^2 STANDARD_DEVIATION 3.22 | 24.40 kg/m^2 STANDARD_DEVIATION 3.24 | 24.19 kg/m^2 STANDARD_DEVIATION 3.31 |
| Compliance With DPP-4 Inhibitors During 4-Week Before Start of Treatment 90 Percent or More | 30 Participants | 60 Participants | 30 Participants |
| Complication of Metabolic Syndrome Had No Presence of Complications | 19 Participants | 38 Participants | 19 Participants |
| Complication of Metabolic Syndrome Had Presence of Complications | 11 Participants | 22 Participants | 11 Participants |
| Diabetes Treatment Satisfaction Questionnaire (DTSQ) at the time of informed consent | 23.7 score on a scale STANDARD_DEVIATION 5.86 | 23.3 score on a scale STANDARD_DEVIATION 5.64 | 23.0 score on a scale STANDARD_DEVIATION 5.48 |
| Duration of diabetes mellitus 3 Years or More | 26 Participants | 55 Participants | 29 Participants |
| Duration of diabetes mellitus Less than 3 Years | 4 Participants | 5 Participants | 1 Participants |
| Experience in Educational Hospitalization on Diabetes Had Experience | 3 Participants | 5 Participants | 2 Participants |
| Experience in Educational Hospitalization on Diabetes Had No Experience | 27 Participants | 55 Participants | 28 Participants |
| Glycosylated Hemoglobin A1c (HbA1c) National Glycohemoglobin Standardization Program (NGSP) | 7.34 percent STANDARD_DEVIATION 0.63 | 7.38 percent STANDARD_DEVIATION 0.74 | 7.41 percent STANDARD_DEVIATION 0.84 |
| Height | 169.2 cm STANDARD_DEVIATION 7.44 | 169.5 cm STANDARD_DEVIATION 6.97 | 169.9 cm STANDARD_DEVIATION 6.58 |
| Number of Oral Drugs/Day at the Start of the Treatment Period, Excluding Study Drug 1 or 2 Tablet(s) | 12 Participants | 21 Participants | 9 Participants |
| Number of Oral Drugs/Day at the Start of the Treatment Period, Excluding Study Drug 3 - 5 Tablets | 13 Participants | 24 Participants | 11 Participants |
| Number of Oral Drugs/Day at the Start of the Treatment Period, Excluding Study Drug 6 Tablets or More | 5 Participants | 15 Participants | 10 Participants |
| Presence of Cohabiter Living alone | 4 Participants | 8 Participants | 4 Participants |
| Presence of Cohabiter Living together | 26 Participants | 52 Participants | 26 Participants |
| Race and Ethnicity Not Collected | — | 0 Participants | — |
| Region of Enrollment Japan | 30 Participants | 60 Participants | 30 Participants |
| Sex: Female, Male Female | 4 Participants | 6 Participants | 2 Participants |
| Sex: Female, Male Male | 26 Participants | 54 Participants | 28 Participants |
| Smoking Habits Had No Smoking Habits | 27 Participants | 50 Participants | 23 Participants |
| Smoking Habits Had Smoking Habits | 3 Participants | 10 Participants | 7 Participants |
| Weight | 70.57 kg STANDARD_DEVIATION 10.79 | 70.22 kg STANDARD_DEVIATION 10.7 | 69.87 kg STANDARD_DEVIATION 10.79 |
| Work status Unemployed | 6 Participants | 13 Participants | 7 Participants |
| Work status Worker | 24 Participants | 47 Participants | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 59 | 0 / 60 |
| other Total, other adverse events | 4 / 59 | 1 / 60 |
| serious Total, serious adverse events | 1 / 59 | 0 / 60 |
Outcome results
Primary
Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period
Participants answered standardized questions about their preference of drug therapy for Type 2 Diabetes Mellitus. Participants selected one choice from the following 4 choices; either once-weekly DPP-4 inhibitor or daily DPP-4 inhibitor, once-weekly DPP-4 inhibitor, daily DPP-4 inhibitor, neither once-weekly DPP-4 inhibitor nor daily DPP-4 inhibitor. Reported data was the number of participants with a choice of either trelagliptin (once-weekly DPP-4 inhibitor) or alogliptin (once-daily DPP-4 inhibitor), trelagliptin, alogliptin, neither trelagliptin nor alogliptin.
Time frame: At Week 16
Population: FAS included all enrolled participants who received either the investigational product or comparator at least once during the study after randomization.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period | Either Trelagliptin or Alogliptin | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period | Trelagliptin | 8 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period | Alogliptin | 18 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period | Neither Trelagliptin nor Alogliptin | 0 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period | Neither Trelagliptin nor Alogliptin | 0 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period | Either Trelagliptin or Alogliptin | 7 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period | Alogliptin | 13 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period | Trelagliptin | 10 Participants |
p-value: 0.0141Mainland-Gart Test
Secondary
Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors
Participants answered standardized questions about their preference of drug therapy for Type 2 Diabetes Mellitus. The preference of drug therapy was categorized by background factors like age (years), gender, height (cm), weight (kg), BMI (kg/m\^2), duration of diabetes (years), work status, alcohol intake history, smoking habits, experience of educational hospitalization on DM, presence of cohabiter, percentage of compliance with DPP-4 inhibitors during 4-weeks before the start of treatment period, number of oral drugs per day at the beginning of treatment period (excluding investigational drug), complication of metabolic syndrome, percentage of HbA1c (NGSP is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at the time of informed consent.
Time frame: At Week 16
Population: FAS included all enrolled participants who received either the investigational product or comparator at least once during the study after randomization.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 60.0<= - <70.0 | 3 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, 18.5 <= - <25.0 | 9 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Work Status, Unemployed | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Work Status, Worker | 9 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 70.0 <= - <80.0 | 8 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), < 7.0% | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Duration of Diabetes, Less than 3 Years | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 80.0 <= - <=Max | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Complication of Metabolic Syndrome | 7 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Duration of Diabetes, 3 Years or More | 10 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, Min <= - <18.5 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Gender, Female | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, 25.0 <= - <=Max | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Gender, Male | 11 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Complication of Metabolic Syndrome | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 6 Tablets or More | 5 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, Min <= - <150 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Age, 65 <= - <75 | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 3 - 5 Tablets | 5 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 150 <= - <160 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Compliance with DPP-4 Inhibitors, 90% or More | 11 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Presence of Cohabiter, Living together | 10 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 160 <= - <170 | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Age, Min <= - <65 | 9 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Presence of Cohabiter, Live alone | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Experience of Educational Hospitalization | 8 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 170 <= - <=Max | 10 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), 8.0%<= | 3 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Experience of Educational Hospitalization | 3 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Smoking Habits | 7 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, Min <= - <50.0 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Smoking Habits | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Non-Drinker | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 50.0 <= - <60.0 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), 7.0%<= - <8.0% | 7 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Occasional Drinker | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Regular Drinker | 5 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Complication of Metabolic Syndrome | 14 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Age, Min <= - <65 | 13 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Age, 65 <= - <75 | 5 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Gender, Male | 16 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Gender, Female | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, Min <= - <150 | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 160 <= - <170 | 9 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 170 <= - <=Max | 7 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 50.0 <= - <60.0 | 5 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 60.0<= - <70.0 | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 70.0 <= - <80.0 | 6 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 80.0 <= - <=Max | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, Min <= - <18.5 | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, 18.5 <= - <25.0 | 9 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, 25.0 <= - <=Max | 8 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Duration of Diabetes, 3 Years or More | 17 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Duration of Diabetes, Less than 3 Years | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Work Status, Worker | 16 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Work Status, Unemployed | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Regular Drinker | 7 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Occasional Drinker | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Non-Drinker | 8 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Smoking Habits | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Smoking Habits | 14 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Experience of Educational Hospitalization | 0 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Experience of Educational Hospitalization | 18 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Presence of Cohabiter, Live alone | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Presence of Cohabiter, Living together | 15 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Compliance with DPP-4 Inhibitors, 90% or More | 18 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 7 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 3 - 5 Tablets | 8 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 6 Tablets or More | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Complication of Metabolic Syndrome | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, Min <= - <50.0 | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), < 7.0% | 6 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), 7.0%<= - <8.0% | 8 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), 8.0%<= | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 150 <= - <160 | 1 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Gender, Male | 27 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 170 <= - <=Max | 15 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Age, 65 <= - <75 | 15 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 13 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Non-Drinker | 8 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, Min <= - <150 | 0 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Experience of Educational Hospitalization | 2 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 3 - 5 Tablets | 11 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Occasional Drinker | 0 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, Min <= - <50.0 | 0 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), 8.0%<= | 6 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 6 Tablets or More | 7 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Age, Min <= - <65 | 16 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Experience of Educational Hospitalization | 29 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Gender, Female | 4 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, 18.5 <= - <25.0 | 18 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Smoking Habits | 2 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, Min <= - <18.5 | 0 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 160 <= - <170 | 14 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, 25.0 <= - <=Max | 13 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 70.0 <= - <80.0 | 7 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 80.0 <= - <=Max | 7 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Complication of Metabolic Syndrome | 14 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Duration of Diabetes, 3 Years or More | 28 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Presence of Cohabiter, Live alone | 4 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 50.0 <= - <60.0 | 5 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Regular Drinker | 23 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Duration of Diabetes, Less than 3 Years | 3 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), 7.0%<= - <8.0% | 14 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Presence of Cohabiter, Living together | 27 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), < 7.0% | 11 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Work Status, Worker | 22 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 150 <= - <160 | 2 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 60.0<= - <70.0 | 12 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Smoking Habits | 29 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Work Status, Unemployed | 9 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Compliance with DPP-4 Inhibitors, 90% or More | 31 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Complication of Metabolic Syndrome | 17 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 50.0 <= - <60.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Regular Drinker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Complication of Metabolic Syndrome | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Occasional Drinker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, Min <= - <50.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Alcohol Intake History, Non-Drinker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Smoking Habits | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 170 <= - <=Max | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Smoking Habits | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), < 7.0% | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Experience of Educational Hospitalization | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 160 <= - <170 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Age, 65 <= - <75 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had No Experience of Educational Hospitalization | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Presence of Cohabiter, Live alone | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, 150 <= - <160 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Presence of Cohabiter, Living together | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), 7.0%<= - <8.0% | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Compliance with DPP-4 Inhibitors, 90% or More | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Height, Min <= - <150 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 80.0 <= - <=Max | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 3 - 5 Tablets | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Gender, Female | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Number of Oral Drugs per Day, 6 Tablets or More | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, Min <= - <18.5 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, 18.5 <= - <25.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | HbA1c (NGSP), 8.0%<= | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | BMI, 25.0 <= - <=Max | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Duration of Diabetes, 3 Years or More | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 70.0 <= - <80.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Had Complication of Metabolic Syndrome | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Duration of Diabetes, Less than 3 Years | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Weight, 60.0<= - <70.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Gender, Male | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Work Status, Worker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Age, Min <= - <65 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors | Work Status, Unemployed | 0 Participants |
Secondary
Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group)
Participants answered standardized questions about their preference of drug therapy for Type 2 Diabetes Mellitus. The preference of drug therapy was categorized by background factors like age (years), gender, height (cm), weight (kg), BMI (kg/m\^2), duration of diabetes (years), work status, alcohol intake history, smoking habits, experience of educational hospitalization on DM, presence of cohabiter, percentage of compliance with DPP-4 inhibitors during 4-weeks before the start of treatment period, number of oral drugs per day at the beginning of treatment period (excluding investigational drug), complication of metabolic syndrome, percentage of HbA1c (NGSP is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at the time of informed consent.
Time frame: At Week 16
Population: FAS included all enrolled participants who received either the investigational product or comparator at least once during the study after randomization.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 60.0<= - <70.0 | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Smoking Habits | 3 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Work Status, Worker | 5 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Complication of Metabolic Syndrome | 3 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 70.0 <= - <80.0 | 5 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Non-Drinker | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), < 7.0% | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Experience of Educational Hospitalization | 6 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 80.0 <= - <=Max | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Experience of Educational Hospitalization | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Gender, Male | 7 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 6 Tablets or More | 5 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, Min <= - <18.5 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Occasional Drinker | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 160 <= - <170 | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Regular Drinker | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, 18.5 <= - <25.0 | 5 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), 8.0%<= | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Presence of Cohabiter, Live alone | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 3 - 5 Tablets | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, 25.0 <= - <=Max | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 170 <= - <=Max | 6 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), 7.0%<= - <8.0% | 6 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Smoking Habits | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Duration of Diabetes, 3 Years or More | 6 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Age, 65 <= - <75 | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Duration of Diabetes, Less than 3 Years | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Complication of Metabolic Syndrome | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Gender, Female | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 50.0 <= - <60.0 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 150 <= - <160 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Age, Min <= - <65 | 5 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Compliance with DPP-4 Inhibitors, 90% or More | 7 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Work Status, Unemployed | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Presence of Cohabiter, Living together | 6 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Work Status, Unemployed | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Age, Min <= - <65 | 8 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Regular Drinker | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), < 7.0% | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Occasional Drinker | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Presence of Cohabiter, Live alone | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Non-Drinker | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 150 <= - <160 | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Smoking Habits | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Experience of Educational Hospitalization | 10 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Smoking Habits | 8 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Experience of Educational Hospitalization | 0 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 160 <= - <170 | 6 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Complication of Metabolic Syndrome | 7 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 170 <= - <=Max | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 50.0 <= - <60.0 | 5 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Age, 65 <= - <75 | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Complication of Metabolic Syndrome | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 60.0<= - <70.0 | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 70.0 <= - <80.0 | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), 7.0%<= - <8.0% | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 6 Tablets or More | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 80.0 <= - <=Max | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, Min <= - <18.5 | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Gender, Male | 9 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 3 - 5 Tablets | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, 18.5 <= - <25.0 | 5 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Presence of Cohabiter, Living together | 9 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, 25.0 <= - <=Max | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 5 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Duration of Diabetes, 3 Years or More | 10 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Duration of Diabetes, Less than 3 Years | 0 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Compliance with DPP-4 Inhibitors, 90% or More | 10 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Work Status, Worker | 9 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Gender, Female | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), 8.0%<= | 4 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Presence of Cohabiter, Living together | 11 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Age, Min <= - <65 | 7 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Duration of Diabetes, 3 Years or More | 13 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Age, 65 <= - <75 | 6 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Gender, Male | 12 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Gender, Female | 1 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 150 <= - <160 | 1 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 160 <= - <170 | 3 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 170 <= - <=Max | 9 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 50.0 <= - <60.0 | 1 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 60.0<= - <70.0 | 7 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 70.0 <= - <80.0 | 2 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 80.0 <= - <=Max | 3 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, Min <= - <18.5 | 0 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, 18.5 <= - <25.0 | 8 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, 25.0 <= - <=Max | 5 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Duration of Diabetes, Less than 3 Years | 0 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Work Status, Worker | 9 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Work Status, Unemployed | 4 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Regular Drinker | 11 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Occasional Drinker | 0 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Non-Drinker | 2 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Smoking Habits | 1 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Smoking Habits | 12 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Experience of Educational Hospitalization | 1 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Experience of Educational Hospitalization | 12 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Presence of Cohabiter, Live alone | 2 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Compliance with DPP-4 Inhibitors, 90% or More | 13 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 4 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 3 - 5 Tablets | 6 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 6 Tablets or More | 3 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Complication of Metabolic Syndrome | 5 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Complication of Metabolic Syndrome | 8 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), < 7.0% | 8 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), 7.0%<= - <8.0% | 3 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), 8.0%<= | 2 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Work Status, Worker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Duration of Diabetes, Less than 3 Years | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), < 7.0% | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Compliance with DPP-4 Inhibitors, 90% or More | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Duration of Diabetes, 3 Years or More | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, 25.0 <= - <=Max | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Gender, Male | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, 18.5 <= - <25.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | BMI, Min <= - <18.5 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Age, 65 <= - <75 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 3 - 5 Tablets | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 80.0 <= - <=Max | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 70.0 <= - <80.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), 8.0%<= | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Number of Oral Drugs per Day, 6 Tablets or More | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 60.0<= - <70.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Weight, 50.0 <= - <60.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | HbA1c (NGSP), 7.0%<= - <8.0% | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Complication of Metabolic Syndrome | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 170 <= - <=Max | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 160 <= - <170 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Age, Min <= - <65 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Complication of Metabolic Syndrome | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Height, 150 <= - <160 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Experience of Educational Hospitalization | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Smoking Habits | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had Smoking Habits | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Gender, Female | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Had No Experience of Educational Hospitalization | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Non-Drinker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Occasional Drinker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Presence of Cohabiter, Living together | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Presence of Cohabiter, Live alone | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Alcohol Intake History, Regular Drinker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group) | Work Status, Unemployed | 0 Participants |
Secondary
Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group)
Participants answered standardized questions about their preference of drug therapy for Type 2 Diabetes Mellitus. The preference of drug therapy was categorized by background factors like age (years), gender, height (cm), weight (kg), BMI (kg/m\^2), duration of diabetes (years), work status, alcohol intake history, smoking habits, experience of educational hospitalization on DM, presence of cohabiter, percentage of compliance with DPP-4 inhibitors during 4-weeks before the start of treatment period, number of oral drugs per day at the beginning of treatment period (excluding investigational drug), complication of metabolic syndrome, percentage of HbA1c (NGSP is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at the time of informed consent.
Time frame: At Week 16
Population: FAS included all enrolled participants who received either the investigational product or comparator at least once during the study after randomization.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Complication of Metabolic Syndrome | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Regular Drinker | 3 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Work Status, Unemployed | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 60.0<= - <70.0 | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 6 Tablets or More | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Work Status, Worker | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Duration of Diabetes, Less than 3 Years | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 70.0 <= - <80.0 | 3 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Gender, Female | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Duration of Diabetes, 3 Years or More | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | BMI, 25.0 <= - <=Max | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 80.0 <= - <=Max | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Age, 65 <= - <75 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | BMI, 18.5 <= - <25.0 | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Compliance with DPP-4 Inhibitors, 90% or More | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 3 - 5 Tablets | 3 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, Min <= - <150 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), 8.0%<= | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Presence of Cohabiter, Living together | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 150 <= - <160 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), < 7.0% | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Presence of Cohabiter, Live alone | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Experience of Educational Hospitalization | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 160 <= - <170 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Complication of Metabolic Syndrome | 3 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Experience of Educational Hospitalization | 2 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Age, Min <= - <65 | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 170 <= - <=Max | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Gender, Male | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Smoking Habits | 4 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Smoking Habits | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, Min <= - <50.0 | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), 7.0%<= - <8.0% | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Non-Drinker | 0 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Occasional Drinker | 1 Participants |
| Trelagliptin 100 mg + Alogliptin 25 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 50.0 <= - <60.0 | 0 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Smoking Habits | 6 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Age, Min <= - <65 | 5 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Age, 65 <= - <75 | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Gender, Male | 7 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Gender, Female | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, Min <= - <150 | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 150 <= - <160 | 0 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 160 <= - <170 | 3 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 170 <= - <=Max | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, Min <= - <50.0 | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 50.0 <= - <60.0 | 0 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 60.0<= - <70.0 | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 70.0 <= - <80.0 | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 80.0 <= - <=Max | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | BMI, 18.5 <= - <25.0 | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | BMI, 25.0 <= - <=Max | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Duration of Diabetes, 3 Years or More | 7 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Duration of Diabetes, Less than 3 Years | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Work Status, Worker | 7 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Work Status, Unemployed | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Regular Drinker | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Occasional Drinker | 0 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Non-Drinker | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Smoking Habits | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Experience of Educational Hospitalization | 0 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Experience of Educational Hospitalization | 8 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Presence of Cohabiter, Live alone | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Presence of Cohabiter, Living together | 6 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Compliance with DPP-4 Inhibitors, 90% or More | 8 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 2 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 3 - 5 Tablets | 5 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Complication of Metabolic Syndrome | 7 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 6 Tablets or More | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Complication of Metabolic Syndrome | 1 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), < 7.0% | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), 7.0%<= - <8.0% | 4 Participants |
| Alogliptin 25 mg + Trelagliptin 100 mg | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), 8.0%<= | 0 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), < 7.0% | 3 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Compliance with DPP-4 Inhibitors, 90% or More | 18 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Smoking Habits | 17 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, Min <= - <150 | 0 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Non-Drinker | 6 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 9 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 160 <= - <170 | 11 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Complication of Metabolic Syndrome | 9 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Experience of Educational Hospitalization | 1 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Complication of Metabolic Syndrome | 9 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Gender, Female | 3 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Occasional Drinker | 0 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), 8.0%<= | 4 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 3 - 5 Tablets | 5 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Regular Drinker | 12 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 80.0 <= - <=Max | 4 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Experience of Educational Hospitalization | 17 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | BMI, 18.5 <= - <25.0 | 10 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Smoking Habits | 1 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 150 <= - <160 | 1 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Age, 65 <= - <75 | 9 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | BMI, 25.0 <= - <=Max | 8 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Presence of Cohabiter, Live alone | 2 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 70.0 <= - <80.0 | 5 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), 7.0%<= - <8.0% | 11 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Duration of Diabetes, 3 Years or More | 15 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, Min <= - <50.0 | 0 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Work Status, Unemployed | 5 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 6 Tablets or More | 4 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Duration of Diabetes, Less than 3 Years | 3 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 170 <= - <=Max | 6 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 60.0<= - <70.0 | 5 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Age, Min <= - <65 | 9 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Work Status, Worker | 13 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Presence of Cohabiter, Living together | 16 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 50.0 <= - <60.0 | 4 Participants |
| Alogliptin Preference | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Gender, Male | 15 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 60.0<= - <70.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Work Status, Unemployed | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), 7.0%<= - <8.0% | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, Min <= - <50.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Occasional Drinker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Complication of Metabolic Syndrome | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Non-Drinker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 170 <= - <=Max | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Age, 65 <= - <75 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Smoking Habits | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 160 <= - <170 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Smoking Habits | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had Experience of Educational Hospitalization | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, 150 <= - <160 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Complication of Metabolic Syndrome | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Had No Experience of Educational Hospitalization | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Presence of Cohabiter, Live alone | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Height, Min <= - <150 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Presence of Cohabiter, Living together | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Compliance with DPP-4 Inhibitors, 90% or More | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), < 7.0% | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 1 or 2 Tablet(s) | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Gender, Female | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Age, Min <= - <65 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Alcohol Intake History, Regular Drinker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | HbA1c (NGSP), 8.0%<= | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 80.0 <= - <=Max | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 3 - 5 Tablets | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | BMI, 18.5 <= - <25.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 70.0 <= - <80.0 | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Gender, Male | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | BMI, 25.0 <= - <=Max | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Duration of Diabetes, 3 Years or More | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Duration of Diabetes, Less than 3 Years | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Number of Oral Drugs per Day, 6 Tablets or More | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Work Status, Worker | 0 Participants |
| Neither Trelagliptin Nor Alogliptin | Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) | Weight, 50.0 <= - <60.0 | 0 Participants |